COMPASS Pathways’ (CMPS) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

COMPASS Pathways (NASDAQ:CMPS)‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a research note issued on Friday,Benzinga reports.

Several other brokerages have also issued reports on CMPS. HC Wainwright reiterated a “buy” rating and set a $45.00 target price on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Stifel Nicolaus began coverage on COMPASS Pathways in a research note on Thursday, February 27th. They issued a “buy” rating and a $11.00 price target on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Finally, Canaccord Genuity Group cut their target price on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways currently has a consensus rating of “Buy” and an average target price of $21.83.

COMPASS Pathways Stock Performance

Shares of COMPASS Pathways stock traded down $0.08 during trading hours on Friday, reaching $3.02. The company had a trading volume of 25,613 shares, compared to its average volume of 756,351. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a one year low of $2.88 and a one year high of $10.31. The firm has a market cap of $279.41 million, a PE ratio of -1.37 and a beta of 2.29. The business has a fifty day simple moving average of $3.87 and a 200 day simple moving average of $4.76.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). On average, analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On COMPASS Pathways

Several institutional investors and hedge funds have recently modified their holdings of CMPS. Tang Capital Management LLC bought a new stake in shares of COMPASS Pathways during the fourth quarter valued at approximately $3,780,000. RTW Investments LP purchased a new position in shares of COMPASS Pathways in the fourth quarter worth $11,714,000. Point72 Asset Management L.P. lifted its holdings in shares of COMPASS Pathways by 15.4% during the fourth quarter. Point72 Asset Management L.P. now owns 67,999 shares of the company’s stock valued at $257,000 after purchasing an additional 9,099 shares in the last quarter. Integral Health Asset Management LLC purchased a new stake in shares of COMPASS Pathways during the fourth quarter valued at $756,000. Finally, Cubist Systematic Strategies LLC increased its holdings in COMPASS Pathways by 205.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 126,636 shares of the company’s stock worth $479,000 after buying an additional 85,213 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.